Contractor
CROSSJECT SA
DIJON
- UEI
- NLXZHCL3NLL3
- Resolved by
- uei
- Confidence
- 1.000
Obligated to date
$108,841,7691
Awards
1
Agencies served
1
Active from Jun 9, 2022 to Sep 23, 2026.
Sign in to watchRecent awards
| Award | Agency | Place | First action | Current value |
|---|---|---|---|---|
| 75A50122C00031 ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGENCY USE AUTHORIZATION (EUA) OR FDA APPROVAL FOR THE TREATMENT OF STATUS EPILEPTICUS SEIZURES IN ADULT AND PEDIATRIC POPULATIONS (2+ | Department of Health and Human Services | — | Jun 9, 2022 | $108,841,769 |
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.
- 1Awards are attributed by Unique Entity Identifier NLXZHCL3NLL3, the government's own recipient identifier, not by name matching.
- 2Award records from USAspending.gov, last refreshed Sep 26, 2026.